Literature DB >> 2335577

Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy.

M L Hartman1, J D Veldhuis, M L Vance, A C Faria, R W Furlanetto, M O Thorner.   

Abstract

Alterations in pulsatile GH release in 13 acromegalic patients (7 men and 6 women) were studied by measuring serum GH concentrations in blood sampled every 5 min over 24 h. Specific properties of pulsatile GH release were quantitated by Cluster analysis, and Fourier expansion time series analysis was used to resolve fixed periodicities underlying GH secretion. Compared with sex-matched controls, 24-h integrated GH concentrations (IGHC; min.mg/L) were elevated 15-fold in the acromegalic men (40 +/- 27 vs. 2.6 +/- 0.35; P = 0.02) and 10-fold in the acromegalic women (43 +/- 19 vs. 4.1 +/- 0.35; P = 0.01). The increase in integrated GH concentrations was accounted for by an increase in the nonpulsatile fraction [men, 31 +/- 20 vs. 0.65 +/- 0.10 (P = 0.001); women, 35 +/- 14 vs. 1.2 +/- 0.10 (P = 0.0008)]; the pulsatile component was not different from that in normal subjects. Acromegalics had an increased number of pulses per 24 h [men, 17 +/- 1.5 vs. 6.7 +/- 1.4 (P = 0.0001); women, 19 +/- 1.6 vs. 11 +/- 1.0 (P = 0.002)] and increased basal GH concentrations [men, interpulse valley mean, 22 +/- 14 vs. 1.4 +/- 0.30 micrograms/L (P = 0.0006); women, 27 +/- 12 vs. 1.3 +/- 0.20 micrograms/L (P = 0.0001)]. The proportion of the mean GH concentration attributable to 24-h rhythmicity was decreased in the acromegalic patients. Five patients studied during biochemical remission (4 after transsphenoidal surgery and 1 during bromocriptine therapy) had GH profiles that resembled those of normal subjects. Pulsatile GH secretion in acromegaly is characterized by augmented basal GH concentrations, increased GH pulse frequency, and an attenuation of the underlying 24-h rhythm. Such a pattern may be secondary to the intrinsic pathology of adenomatous somatotrophs and/or the effects of altered hypothalamic regulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335577     DOI: 10.1210/jcem-70-5-1375

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

2.  Effect of glycemic control on growth hormone and IGFBP-1 secretion in patients with type I diabetes mellitus.

Authors:  L R Salgado; M Semer; M Nery; M Knoepfelmacher; A C Lerário; G Póvoa; S Jana; S M Villares; B L Wajchenberg; B Liberman; W Nicolau
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

3.  Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly.

Authors:  H S Chen; H D Lin
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

4.  Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess.

Authors:  Alison M Boyce; McKinley Glover; Marilyn H Kelly; Beth A Brillante; John A Butman; Edmond J Fitzgibbon; Carmen C Brewer; Christopher K Zalewski; Carolee M Cutler Peck; H Jeffrey Kim; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2012-10-23       Impact factor: 5.958

Review 5.  Pitfalls in the biochemical assessment of acromegaly.

Authors:  Pamela U Freda
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

6.  Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.

Authors:  M L Hartman; S M Pincus; M L Johnson; D H Matthews; L M Faunt; M L Vance; M O Thorner; J D Veldhuis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models.

Authors:  Katica Bajuk Studen; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

8.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 9.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

10.  Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.

Authors:  C A Jaffe; R D Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.